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Abstract
The antibacterial soap additive triclocarban (TCC) is widely used in personal care products. TCC
has a high environmental persistence. We developed and validated a sensitive online solid phase
extraction-LC-MS/MS method to rapidly analyze TCC and its major metabolites in urine and
other biological samples to assess human exposure. We measured human urine concentrations 0–
72 h after showering with a commercial bar soap containing 0.6% TCC. The major route of renal
elimination was excretion as N-glucuronides. The absorption was estimated at 0.6% of the 70±15
mg TCC in the soap used. The TCC N-glucuronide urine concentration varied widely among the
subjects and continuous daily use of the soap led to steady state levels of excretion. In order to
assess potential biological effects arising from this exposure we screened TCC for the inhibition of
human enzymes in vitro. We demonstrate that TCC is a potent inhibitor of the enzyme soluble
epoxide hydrolase (sEH), whereas TCC′s major metabolites lack strong inhibitory activity.
Topical administration of TCC at similar levels to rats in a preliminary in vivo study however
failed to alter plasma biomarkers of sEH activity. Overall the analytical strategy described here
revealed that use of TCC soap causes exposure levels that warrant further evaluation.
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Introduction
Triclocarban (TCC, 3,4,4′-Trichlorocarbanilide) is widely used as an antibacterial agent in
soaps1. Many of the antimicrobial bar soaps sold in the US contain up to 1.5% of TCC,
amounting to a million pounds of this chemical used every year2, 3. Due to its environmental
persistence and widespread use, TCC was found in surface water in concentrations up to μg/
Llevels and recent studies show that TCC accumulates in snails and algae2, 4, 5. Moreover,
the Targeted National Sewage Sludge Survey published in 2009 (US EPA) reports the
detection of TCC in all 84 sewage samples analyzed. TCC was found at concentrations up to
0.44 g/kg, the highest levels of all synthetic compounds included in the study6. Based on the
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toxicological studies from the 1970s, the European Union regard the use of TCC in personal
care products (PCP) as safe7. However, recent findings from our group indicate that TCC
has significant biological effects on mammalian targets. At high concentrations, it might act
as an endocrine disruptor by enhancing the action of testosterone and other steroids1, 8.
Moreover, it was recently shown that oxidative metabolism of TCC may lead to reactive
intermediates, which can covalently bind to proteins9. A high-throughput in vitro screening
study also showed, that TCC inhibits potently the soluble epoxide hydrolase (sEH)10. Its
inhibitory potency is similar to many sEH inhibitors, which in vivo alter the biological
regulation of inflammation, pain and blood pressure11–13. Taken together, the high
persistence of TCC in the environment, direct exposure by humans in PCP, and particularly
the potent inhibition of sEH suggest that exposure to TCC could influence human health.
In order to assess this risk that TCC influences human health, human exposure levels have to
be evaluated. Most human exposure studies on TCC were carried out in the 1970s using 14C
labeled compound14–18. Studies demonstrated that TCC is extensively metabolized in
rodents, monkeys and humans15, 19–23. Cytochrome P-450 monooxygenases are thought to
be largely responsible for the extensive oxidative metabolism. The main phase I metabolites
in all species are monohydroxylated-TCC derivatives, bearing a hydroxyl function in ortho
position to the aniline group15, 19–23. The sulfate conjugate of this 2′OH-TCC is the major
metabolite found in human and monkey plasma though to a smaller extent 3′-OH-TCC has
also been detected15, 20, 24. A method able to quantify TCC and all these metabolites is
necessary to accurately assess human exposure to TCC. Recently, several sensitive LC
electro-spray-ionization (ESI) MS methods were developed for the detection and
quantification of TCC including, in some cases, the two byproducts of its synthesis,
diclocarban (DCC, 4,4′-Dichlorocarbanilide) and 3′Cl-TCC. These methods were applied to
environmental samples including water and sludge3, 25–28. However, these methods did not
include the quantification of major metabolites. Moreover, they are not designed to
investigate biological samples. Online solid phase extraction (SPE) is a fast sample
preparation approach for the analysis of biological samples which can be fully
automated29–32. This approach was successfully applied for the detection of TCC among
other contaminants in breast milk33. This multianalyte method allows the detection of TCC
only and not TCC metabolites and it employs a relatively long runtime of 24 minutes33.
Therefore in the present study, a fast online-solid phase extraction (SPE)-LC-ESI-MS/MS
method specifically designed for the monitoring of TCC and its metabolites (2′OH-TCC,
3′OH-TCC and 2-SO3-O-TCC as well as its analogs DCC and 3′Cl-TCC) in plasma and
urine was developed and validated. This method was utilized to investigate the urine
concentration of TCC in human volunteers. Exposure to TCC was accomplished following
showering with a commercial soap containing TCC. In order to extrapolate the potential of
eliciting biological effects, we tested a comparable amount of TCC administered topically in
a cream to rats and monitored biomarkers of sEH activity in vivo and evaluated the
inhibitory potency of the metabolites in vitro.
Material and Methods
Chemicals
3,4,4'-Trichlorocarbanilide (Triclorcarban, TCC) was purchased from Aldrich (St Louis,
MO) and further purified (≥ 99.9%) by repeated re-crystallization. Beta-glucuronidase
(GUS) from Helix pomatia Type I and Type II and GUS Type VA from E. coli were
obtained from Sigma Aldrich (St. Louis, MO). The internal standard I.S. (4-
Chlorphenyl 13C6)-TCC (99% 13C) was obtained from Cambridge Isotope Laboratories Inc.
(Andover, MA). All other chemicals were from Fisher Scientific (Pittsburgh, PA) and were
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of the highest purityavailable. The chemical structures of the analytes are displayed in Fig
S1.
Synthesis of standards
The TCC congeners, 4,4'-dichlorocarbanilide (DCC) and 3,3′,4,4'-tetrachlorocarbanilide
(3′Cl-TCC), and TCC metabolites, 2′OH-TCC, 3′OH-TCC and 2′SO3O-TCC were
synthesized using the appropriate isocyanate and amine as described previously8, 19, 34. The
purity of the products was higher than 99% based on the peak areas following HPLC-UV-
analysis at 270 nm.
Online-SPE-LC-MS/MS analysis of TCC and its analogs
Online SPE-LC analysis was performed in back-flush mode as described in the SI
Preparation of standard solutions and spiked samples
Analyte stock solutions (10 mM) were prepared in DMSO and stored at −20°C. A solution
of I.S. was prepared in ACN/HAc 98/2 to a final concentration of 20 nM for 1:1 and 12.5
nM for 1:4 dilutions with the sample. For calibration, a multi standard solution (100 μM in
ACN) was prepared from stock solution and sequentially diluted and mixed with I.S.
solution 1:1 (v/v) yielding concentrations of 0.015–1500 nM of each analyte. For
determination of recovery rates, spiked sample solutions were prepared by mixing 90 μL of
pooled blank human urine and pooled blank rat plasma with 10 μl of 1000 nM, 300 nM and
100 nM of I.S. free standard solutions, respectively. Each spiked solution was prepared in
triplicate and was treated like other samples.
Human exposure to TCC following showering with a TCC containing soap
TCC exposure was investigated in a group of six healthy volunteers (Information about the
subjects is provided in the SI). This study was reviewed and approved by the UC Davis IRB
committee and informed consent forms were obtained from the subjects prior to the study.
The volunteers were questioned about their use of TCC containing products, and instructed
not to use them during the sampling period. Directly before the exposure a urine sample was
collected from the volunteers (t=0 h). The volunteers were then asked to take a shower with
commercial 0.6% TCC containing soap (Dial Gold soap, Dial/Henkel, St. Louis, MO)
obtained locally. The individuals took a shower, rubbing soap throughout the whole body
except for head and genitals. In order to minimize inter-individual differences in shower
procedures, the individuals let the foam stand for 15 min prior to wash off. Aliquots from
each urination over a time span of 24–48 hours, and a single sample after 72 h were
collected and stored at −20°C until analysis. To normalize the urine samples by renal fluid
excretion rate, the creatinine concentrations of all urine samples were determined by a
standard photometric method using 2,4,6-trinitrophenol35.
Sample preparation
For analyses, 50–100 μL aliquots of samples were mixed with I.S. solution 1/1 (v/v),
vortexed and centrifuged at 16,000 × g at 4°C for 5 min. The supernatant was directly
injected into the online-SPE-LC-ESI-MS/MS system.
Acid TCC conjugate hydrolysis was carried out as described by Scharpf et al. with minor
modifications14. Hydrochloric acid (100 μL) was added to 500 μL of urine to a final acid
concentration of 1 M in a 3 mL glass vial with a screw cap. The mixtures were vortexed and
heated for 20 min to 100 °C, cooled down on ice and neutralized with 90 μL of 6 M aqueous
NaOH. An aliquot of the resulting solution was subsequently mixed with I.S. solution 1:4 (v/
v) and analyzed in the same way as the other samples. For enzymatic hydrolysis, the
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samples were mixed (9:1, sample:enzyme) with GUS form E. coli type VA (10,000 units/
mL in 100 mM potassium phosphate buffer) and incubated overnight at 37°C. The
optimization of the conjugate hydrolysis is described in the SI.
Topical administration of TCC to rats
Four male rats (Charles River Inc. Boston, MA) with a body weight of 485±20 g were used.
This study was approved by the institutional UC Davis Animal Care and Use Committee.
Animals were housed in UC Davis facilities with access to food and water ad libitum,. In
order to generate a human equivalent exposure to TCC in rats we formulated TCC in a
cream. The cream was prepared by dissolving TCC in PEG400 and mixing this 1:9 (v:v)
with commercially available VaniCream® as described to give a final TCC concentration of
1% (v:wt)13. This amount is similar to the concentrations found in commercially available
soaps. Before the administration of TCC, a blood sample (500 μL) was taken from the tail
vein of each animal 2 hours after treatment with TCC free VaniCream. These baseline
samples from the first week served as controls. One week following the baseline sampling
Vanicream formulated with TCC (a volume of 75 μL cream corresponding to a topical dose
of 1.5 mg/kg bodyweight) was applied and blood (500 μL) was sampled 2 hours following
topical administration. In the following week Vanicream formulated with TCC (a volume of
200 μL cream corresponding to a topical dose of 4 mg/kg) was again administered and
blood was sampled 2 hours following administration. The cream was administered to one
hind paw of the rat and gently rubbed for 1 min. until the cream disappeared into the paw.
The rats were monitored by the investigator between application and sample collection and
they did not lick the paw.Thus the possibility of oral absorption can be excluded.
Plasma was separated from heparinized blood samples and was stored at −70°C until
analysis. To monitor TCC, 20 μL and for its metabolites 18 μl of plasma were used. For the
quantitative analysis of oxylipins 200 μL of plasma were analyzed by LCMS/MS, as
described by Yang et al. with modifications36 (see SI). Additionally single urine sample
from the animals receiving the highest dose were collected 2–8 h after treatment and
analysed for the presence of TCC-N-glucuronides.
In vitro measurement of sEH inhibition by TCC and its metabolites
The potency of TCC and its metabolites was determined for the recombinant human and rat
sEH enyzmes. Baculovirus expressed, purified enzymes were used in all assays37. The
inhibitory potencies were measured using two independent activity assays, one based on the
generation of a fluorescent product38 and the other based on the hydrolysis of a putative
endogenous substrate: 14,15-epoxyeicosatrienoic acid (14,15-EET) using LC-MS detection
of the resulting diol as described39.
In vitro screening for inhibition of human enzymes
The effects of TCC and its metabolites on the activity of human esterases, microsomal
amidase, Cytochrome P-450 monooxyganases, glutathione-S-tranferases and mitochondrial
epoxide hydrolase were investigated in a standard battery of in vitro assays described in the
SI.
Data analysis
All results are reported as mean of three determinations. For rat plasma the variation is
reported as standard error (SE). Oxylipin data were analyzed by ANOVA followed by
Dunnett's 2-sided t-test for between group comparisons.
Schebb et al. Page 4
Environ Sci Technol. Author manuscript; available in PMC 2012 October 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Results
Development of an automated analytical method for TCC exposure assessment
In order to rapidly analyze TCC and its metabolites in urine and plasma samples, an online
SPE-LC-ESI-MS/MS method allowing the direct injection of these crude biological samples
(a detailed description is given in SI) was developed and optimized. The method allows
baseline separation, selective analysis and quantification of TCC, its metabolites and two
analogs in less than 7 minutes including the online SPE step. The limit of detection (LOD,
S/N = 3) for TCC and most of the analytes was 0.15 nM (50 pg/mL) equivalent to 6 fmol on
the column (Table 1). The method provided a broad linear range of detection, over 3 orders
of magnitude (r2≥0.99, Table 1). Using plasma and urine samples spiked with 10, 30 and
100 nM of the analytes, we observed a near perfect accuracy for all compounds, with a mean
recovery rate of 104 ± 8% for both urine and plasma (table S2). In addition to the high
accuracy, the method precision was also excellent with an inter sample variation of less than
5% and an intra sample variation of less than 10% for all analytes (table S2). Thus, the direct
injection of crude samples after addition of I.S. and centrifugation in the fully automated
ultra-fast online-SPE-LC-MS/MS did not compromise the analytical performance and is
ideally suited for the exposure measurement of TCC.
Investigation of human exposure to TCC following showering with a TCC containing soap
The findings from Hiles and Birch indicate that the renal excretion is suitable for the
investigation of human exposure to TCC15. Therefore we chose urine analysis for this study.
The dry weight of the soap bars were determined before and after shower by six human
volunteers (A–F). The mean soap consumption was 11.7±2.6 g (70±15 mg TCC)
corresponding to an average a maximal topical dose of 1 mg/Kg bodyweight (40 mg/m2
body surface area). This soap consumption is consistent with earlier findings from Howes
and Black, who reported a soap consumption of 13.75 ± 4.40 g per use16. Subjects B
through F did not use other TCC containing PCPs prior to or after the exposure. Subject A
however declared using 0.6% TCC containing soap on a daily basis. This subject was
instructed to abstainfrom using TCC containing soap for 3 weeks after the experiment to
monitor the decline in TCC levels and obtain a baseline urine sample. This subject then
restarted regular use and provided further urine samples.
Direct urine analysis—In all samples analyzed TCC was barely detectable and only a
few samples exceeded the LOQ (0.3 nM in urine).. The TCC concentration reached an apex
between 10–18 h after exposure with a maximum concentration of 0.75 nM (Fig. 1). The
main oxidative metabolite, 2′OH-TCC, displayed a similar profile to TCC and only a few
samples exceeded the LOQ (Fig. 1). Neither 3′OH-TCC nor the conjugate 2′SO3-O-TCC
was detectable in any of the urine samples in quantifiable amounts. Thus urine concentration
of TCC including its oxidative metabolites is negligible since less than 1 ng/mL is excreted
in urine. However, TCC is excreted in urine in humans and monkey after direct
glucuronidation14, 15, 20, 22. Therefore, the urine samples were screened for the resulting
TCC-N-glucuronides (TCC-N-G) by LC-MS/MS. Large peaks of these metabolites were
detected in the urine of all the exposed subjects (see, SI).
Urine analysis after hydrolysis—Reference compounds or synthetic methods for the
TCC-N-Gs are not available. Thus, to quantify the total amount of TCC excreted, the
conjugates were hydrolyzed prior to analysis. The measured concentration of 2′-OH-TCC
and 3′OH-TCC did not increase after the hydrolysis. Therefore, oxidative TCC metabolites
are not excreted in relevant amounts via a renal route as conjugates nor as aglycons (see
above). In contrast, the measured quantity of TCC in urine increases dramatically after acid
hydrolysis (Fig. 1–2). The excretion profile of the liberated TCC over the post exposure time
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period is perfectly consistent with the semi-quantitative profile of the peak areas for the
TCC-N-Gs in all volunteers. (Fig. 2 and Fig. S11). These findings strongly support earlier
reports that renal excretion of TCC is almost exclusively through N-glucuronidated
metabolites14, 15, 20, 22.
The highest concentrations of TCC-N-Gs measured as liberated TCC occurred 10–24 hours
after exposure (Fig. 2). Despite using the same showering procedure and comparable soap
consumption a massive inter-individual variation in the maximal TCC concentration was
determined (119 to 1013 nM, table S4). Moreover the urinary excretion of TCC-N-G
profiles normalized by creatinine content also varied significantly (Fig. 2). Volunteers A, B
and D displayed a steep increase in the TCC excretion 0–12 h after exposure, which
decreased in a biphasic manner. The renal excretion of volunteers C, D and E increased
more slowly and the urinary concentration remained almost constant over a period of 12–36
h after exposure. Overall, the data suggest that complete clearance required more than 72 h
(Fig. 2). During repeated daily showering with TCC containing soap, the excretion of TCC-
N-Gs reached a steady level over time, as demonstrated for volunteer A with a TCC g−1
creatinine level of 79±20 μg or 420±242 nM TCC-N-Gs (Fig. 2).
Two independent 14C exposure studies in humans reported that approximately 25% of the
TCC absorbed was excreted in the urine14, 15. Thus the total absorbed amount of TCC from
the single shower can be calculated based on the total urine excretion. However, since only
aliquots of each urination over the excretion period were collected the volume of the urine
samples and thus the total excreted amount is unknown. The approximate extent of urinary
TCC-N-G excretion can be estimated despite the lack of total volume of urination over the
excretion period. The daily urinary creatinine excretion is in most individuals relatively
constant, with an estimated mean of 1.5 g/24 h40 and the volume of each urination is
between 0.2–0.7 L (limited by bladder size). With these assumptions a volume was assigned
to each urine sample, for the highest and the lowest possible total TCC-N-Gs excretion (see
details and formula in the SI). A wide but defined range for each subject, ranging from 95–
290 μg TCC for volunteer A to 14–42 μg TCC for volunteer F was found (table S4, mean of
all subjects, 110±30 μg TCC).. Taking into account that 25% of TCC is excreted in the
urine14, 15, it can be roughly estimated that on average 0.5±0.1 mg per shower per person
was absorbed.. This corresponds to an absorbed portion of 0.6±0.2% of the TCC amount
applied with the soap, consistent with the findings of Scharpf et al., who report 0.39% after a
similar whole body shower experiment14.
Bioactivity of TCC
In order to investigate if TCC exposure following showering can alter the activity of sEH,
we administered a comparable topical dose of 1.5 mg/kg BW and a higher dose of 4 mg/kg
BW topically to rats. In contrast to the human study, in which TCC was washed off after 15
min, in the rat study TCC was administered in a cream. Thus we anticipated that this route
of administration led to a higher or at least similar absorption to human exposure.The
plasma levels of TCC reached a mean of 16 nM for the low dose and 94 nM for the high
dose animal group (Fig. S12). Notably glucuronide hydrolysis of plasma samples with GUS
isozymes did not change the TCC concentration. In urine samples collected from rats no
TCC-N-Gs were detected. This finding supports the earlier observations that in the rat TCC
is not metabolized by N-glucuronidation19–21. No free 2′OH-TCC and 3′OH-TCC was
detected in rat plasma. Following GUS treatment low amounts of 9 nM of 2′OH-TCC and
approximately 1 nM of 3′OH-TCC were detected in the high dose group. In both high and
low dose groups substantial concentrations of 2′SO3-O-TCC (>1600 nM), the main known
TCC metabolite in rat and human plasma was found (Fig. S12)20. These plasma levels
indicate that a significant portion of the topically administered TCC was absorbed through
the paw skin in both groups.
Schebb et al. Page 6
Environ Sci Technol. Author manuscript; available in PMC 2012 October 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Next, we investigated if these plasma levels corresponded to changes in the biomarkers of
sEH activity in the plasma. Plasma levels of epoxy-fatty-acids and their corresponding sEH
generated degradation products, the dihydroxy-fatty-acids, from arachidonic acid and
docosahexaenoic acid were quantified following topical administration of TCC. The ratio of
epoxy to dihydroxy fatty acids is a reliable measure of in vivo sEH activity11, 41. Significant
changes in the ratio of epoxy to dihydroxy fatty acids were not observed in either the low
dose or the high dose groups (Fig. S13). Since the ratio of epoxy to dihydroxy fatty acids
reflects systemic inhibition of sEH11, we conclude that topical TCC doses did not
significantly alter systemic sEH activity.
In order to evaluate the in vitro potency of TCC and its metabolites as inhibitors of human
and rat sEH, the IC50 values were determined utilizing two independent methods, one
employing a fluorescent substrate andthe other employing an endogenous substrate of sEH
14(15)EpETrE38, 39. The potency determined for TCC inhibitor with the fluorescence assay
are well in line with the natural substrate (Table 2) and previously reported values10. The
human and the rat sEH are inhibited to a similar degree by TCC regardless of the method
used. All TCC metabolites show lower inhibition potency than the parent compound (Table
2). In particular the main plasma metabolite 2′SO3O-TCC bearing a bulky sulphate group
ortho to the urea moiety, reduces the inhibitory activity towards sEH about 100 fold. Thus,
the metabolism of TCC to these metabolites leads to a biological deactivation of TCC with
respect to sEH inhibition.
In the in vitro screening for other inhibitory potencies , no effect of TCC and its metabolites
was detected on the activity of human carboxylesterases, fatty acid amidase, microsomal
epoxide hydrolase, cytochrome P450 activity and glutathione S-transferases.
Discussion
An analytical method suited for biological samples is indispensable for the determination of
human exposure to TCC. The first aim of our study was to develop a rapid, accurate and
robust analytical approach for the parallel quantification of TCC, its analogs and metabolites
in biological fluids. Through the application of online-SPE sample preparation prior to LC-
MS/MS analysis, sample preparation was minimized. Overall, only four steps required
manual labour, (i) sample collection (ii) mixing with I.S. solution (iii) centrifugation and (iv)
transferring the supernatant to the vial. Considering that 30 samples are centrifuged at the
same time, cumulative hands on preparation time required per sample is less than 1 min per
sample. The online SPE-LC-ESI-MS/MS approach developed herein is not only rapid (7
min/sample), but has excellent accuracy and precision for urine and plasma samples. Due to
its sensitivity, it is possible to accurately monitor TCC and concurrently its major oxidative
metabolites in these biological samples without the need to expose human subjects to
radioactivity as described earlier14, 15.
Following showering with a soap containing 0.6% TCC, the renal excretion profile obtained,
including the presence of TCC-N-Gs as major metabolites and the lack of oxidative
metabolites, is consistent with all previous studies on the human metabolism of
TCC15, 20, 42. . The levels of TCC-N-G (Fig. 2) are consistently higher than those reported
from previous showering or bathing studies with TCC containing soaps. Specifically,
Gruenke et al. reported 30 ng/mL TCC-N-Gs (60 nM) in the urine of users of TCC
containing bar soaps, though the TCC content of these soaps and bathing procedures were
not reported42. Interestingly, Howes and Black did not find TCC (<25 ng/mL) in the urine of
human subjects after intensive 28-day bathing with 2% TCC containing soap16. However,
this is most likely due to a lack of appropriate conjugate hydrolysis.
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In contrast to earlier human exposure studies, here the amounts of excreted TCC in urine
were quantified in each urination following exposure. Therefore we demonstrated for the
first time that renal excretion of TCC varies widely among individual subjects (Fig. 2). The
maximal TCC-N-Gs concentrations in the urine were detected 12–24h after exposure with
up to a 10-fold variation among individuals (table S4). These differences did not correlate
with age, height or weight BMI and body surface area of the volunteers (Table S3) and are
most likely due to individual differences in absorption, distribution, metabolism and
excretion. The total clearance of TCC in urine following a single exposure required
approximately 72 hr. In order to investigate if TCC accumulated due to its slow excretion,
we quantified the urine concentrations of TCC and its metabolites over a time period of two
weeks of daily showering with TCC in a single individual. No accumulation of TCC or its
metabolites was detected (Fig. 2), but urinary excretion reached a constant level of 79±20
μg TCC-N-Gs g−1 creatinine indicating a steady state of TCC body burden.
The large amount of TCC extracted as TCC-N-Gs via the urine in the subjects demonstrates
that a relevant portion of TCC (70±15 mg, equivalent to a topical dose 1 mg/kg BW) was
absorbed after showering. Considering a renal excretion rate of 25%14, 15 and a constant
creatinine excretion rate of 1.5 g/24 h, we estimated that the mean absorption of TCC was
0.5±0.1 mg corresponding to 0.6±0.2% of the dose applied (a detailed description of the
model used is given in SI). This result is consistent with previous findings of 0.4%
absorption of the TCC applied in a similar showering study using 14C labelled TCC14. This
good correlation argues that the TCC-N-Gs levels in urine are highly predictive of the
human TCC exposure and TCC-N-Gs levels are ideally suited for monitoring TCC
exposure.
Our in vitro screening results indicate that TCC does not affect the activity of human
carboxylesterases, fatty acid amidase, microsomal epoxide hydrolases, cytochrome P450
and glutathione S-transferases. However we could show with two independent methods that
TCC is a nanomolar inhibitor of sEH. TCC exhibits a similar inhibitory potency (IC50) when
recombinant human and rat enzymes are compared (Table 2). Thus, the rat may be a suitable
model for humans when investigating the biological effects of TCC mediated by sEH
inhibition. Since the preliminary rat exposure study described here did not lead to systemic
inhibition of sEH as measured by oxylipin profiles (Fig. S13), it seems possible that the
systemic concentrations of free TCC (non-conjugated) found in humans through showering
may not be sufficient to cause effects through sEH inhibition. However at the site of topical
application, the TCC concentration might reach levels which lead to local effects via sEH
inhibition. Possible reasons for the lack of systemic effects of TCC could be non-covalent
protein binding, causing a low uptake into the cells. A key finding of this study is the
deactivation of the inhibitory potency of TCC on sEH by its metabolism. As demonstrated in
this study all investigated TCC metabolites show a lower potency than the parent compound
(Table 2). The in vitro potency of TCC-N-Gs was not determined since reference
compounds were not available. However, based on the extensive SAR of sEH inhibitors it is
highly unlikely that these major urinary metabolites would inhibit sEH43–45. We predict that
the glucuronic acid group would prevent hydrogen binding of the urea moiety in the active
site of the enzyme, and based on our crystal structure data TCC-N-G′s are too large to fit in
the catalytic pocket.
Overall our human exposure study in a small group of subjectsshowed that a portion of the
TCC present in bar soaps is absorbed through the skin and is excreted in urine as N-
glucuronides. These urinary glucuronides appear to be valuable biomarkers of TCC
exposure.. TCC is a nanomolar inhibitor of sEH, and inhibition of this enzyme has been
shown to have profound though largely beneficial effects on mammalian physiology. Our
studies of TCC exposure in human volunteers using a commercial soap when compared to
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preliminary exposure and efficacy data in the rat suggest that such TCC exposures are
unlikely to elicit systemic changes based on sEH inhibition. However, local dermal effects
cannot be ruled out. The TCC exposures found following showering also indicate that a
careful risk benefit analysis of TCC in personal care products should be undertaken. In
particular, long term exposure studies in humans that include bio-monitoring of TCC in
blood should be carried out to evaluate if exposure after using PCPs containing up to 1.5%
TCC provide a sufficient margin of safety. With the online-SPE-LC-MS/MS method
described herein, we provide an excellent analytical tool to answer these questions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Levels of TCC and its metabolite 2′OH-TCC in the urine of volunteer B following exposure
following showering. The results of direct urine analysis without conjugate cleavage are
shown as mean values and standard deviation of three direct injections. 3′OH-TCC and
2′SO3-O-TCC did not exceed LOQ in any of the samples.
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Fig. 2.
TCC concentration in the urine after conjugate hydrolysis. A. Line graph of TCC levels in
the urine of six healthy volunteers. B. Volunteer A, a regular TCC-soap user re-started his/
her normal use of soap containing 0.6% TCC after 18 days of abstinence. The concentration
in urine (mean and SD of three injections) normalized by the creatinine content of the urine
is demonstrated
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Table 1
Performance of the new online solid phase extraction-LC-MS/MS method. The observed retention times, the
dynamic range of for each analyte and the limit of detection (LOD) are presented.
analyte retention time (min) dynamic range (nM) r2 LOD [nM]; [fmol on column]
2′SO4-TCC 2.15 ± 0.03 0.15 – 100 0.997 0.05; 1
3′OH-TCC 2.38 ± 0.02 0.15 – 300 0.999 0.05; 1
DCC 2.92 ± 0.02 0.15 – 500 0.999 0.05; 1
2′OH-TCC 3.52 ± 0.03 0.15 – 500 0.999 0.05; 1
TCC 3.92 ± 0.03 0.15 – 500 0.999 0.05; 1
3′CI-TCC 4.77 ± 0.03 0.3 – 500 0.999 0.1; 2
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Table 2
Inhibitory potency of TCC on sEH. Potency (IC50 values) for TCC and its metabolites were determined using
the recombinant human and rat sEH with the fluorescence assay (substrate: cyano(6-methoxy-naphthalen-2-
yl)methyl trans-[{3-phenyloxiran-2-yl)methyl] carbonate) and alternatively using the LC-MS/MS based assay
with 14(15)-EpETrE as the natural substrate.
compound
fluorescence assay IC50 [nM] LC-MS/MS assay IC50 [nM]
human rat human rat
TCC 39 ± 3 27 ± 6 24 ± 5 18 ± 1
2′-OH-TCC 284 ± 19 926 ± 60 368 ± 51 421 ± 53
2′SO3-O-TCC 1440 ± 130 1640 ± 53 1320 ± 26 1050 ± 130
3′-OH-TCC 133 ± 17 48 ± 8 171 ± 25 24 ± 12
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